Skip to main content
Figure 5 | BMC Pharmacology and Toxicology

Figure 5

From: Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells

Figure 5

Modulation of the UIC2 epitope. In the Panel A and B the binding profiles of the mAb UIC2 on CEM-VBL10 MDR cells are shown (red histogram); incubation of the cells with RALT (25 and 50 μg/mL) does not interfere with mAb UIC2 binding (green histogram). Conversely, a marked shift of mAb binding UIC2 is observed incubating CEM-VBL10 cells with VBL (10 μg/mL) (Panel C, green histogram). The filled profile represents cells stained with secondary antibody alone.

Back to article page